ChoA Pharmaceutical Proposes 5-to-1 Reverse Stock Split for Price Stabilization and Value Enhancement - Extraordinary General Meeting in July 2026
ChoA Pharmaceutical convened an extraordinary general meeting on July 6, 2026, to approve a 5-to-1 reverse stock split and related amendment to its articles of incorporation.
The reverse split changes the par value from 500 to 2,500 KRW and reduces outstanding shares from 30,979,827 to approximately 6,195,965 shares, aiming to stabilize the stock price and enhance corporate value by maintaining an appropriate number of shares in circulation.
Existing shareholders will retain proportional ownership with no dilution, while fractional shares will be compensated in cash. The total capital remains unchanged at approximately 15.489 billion KRW.
[AI Summary]The reverse stock split is a defensive measure to boost share price without capital raising, resulting in no dilution for existing shareholders. However, the trading suspension period and fractional share handling pose minor risks, while the reduction in float could positively impact short-term stock price performance.